Reply to S.D. Lucio.
Publication
, Journal Article
Lyman, GH; Zon, R; Harvey, RD; Schilsky, RL
Published in: J Clin Oncol
July 10, 2018
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
July 10, 2018
Volume
36
Issue
20
Start / End Page
2127
Location
United States
Related Subject Headings
- United States
- Skin Ulcer
- Oncology & Carcinogenesis
- Medical Oncology
- Humans
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Zon, R., Harvey, R. D., & Schilsky, R. L. (2018). Reply to S.D. Lucio. J Clin Oncol, 36(20), 2127. https://doi.org/10.1200/JCO.2018.79.1780
Lyman, Gary H., Robin Zon, R Donald Harvey, and Richard L. Schilsky. “Reply to S.D. Lucio.” J Clin Oncol 36, no. 20 (July 10, 2018): 2127. https://doi.org/10.1200/JCO.2018.79.1780.
Lyman GH, Zon R, Harvey RD, Schilsky RL. Reply to S.D. Lucio. J Clin Oncol. 2018 Jul 10;36(20):2127.
Lyman, Gary H., et al. “Reply to S.D. Lucio.” J Clin Oncol, vol. 36, no. 20, July 2018, p. 2127. Pubmed, doi:10.1200/JCO.2018.79.1780.
Lyman GH, Zon R, Harvey RD, Schilsky RL. Reply to S.D. Lucio. J Clin Oncol. 2018 Jul 10;36(20):2127.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
July 10, 2018
Volume
36
Issue
20
Start / End Page
2127
Location
United States
Related Subject Headings
- United States
- Skin Ulcer
- Oncology & Carcinogenesis
- Medical Oncology
- Humans
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences